Rich CRDMO pipeline drives sustainable high growth
"R"
274,212
2020.7 - 2021.6
Individually synthesized
compounds
1,113 Preclinical & Phase I
"D"
220 Phase II
48 Phase III
"M"32
Commercial
Delivered in 2020.7-2021.6
A dominant leader in China chemistry-based CRDMO market
2020 Chemistry Based Revenue
(¥ Million RMB)
9,531
WuXi Chemistry
Competitor 1
Competitor 2
Competitor 3
Competitor 4
Source: companies annual reports and investor analysis report
15 sites across the globe continue to expand
China
Shanghai Waigaoqiao
Shanghai Zhangjiang
Tianjin
R D M
R
R
Shanghai Jinshan
Changzhou, Jiangsu
Changshu, Jiangsu
D M
D M
M
United States
San Francisco, CA
San Diego, CA
Middletown, DE
Wuhan, Hubei
Chengdu, Sichuan
R
R
Taixing, Jiangsu
Wuxi city, Jiangsu
M
D M
Switzerland
Couvet, Neuchâtel
Qidong, Jiangsu
R
R
Research
7
D Development 5
M Manufacturing 9
RD MMM
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
WuXi AppTec Co. Ltd. published this content on 23 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2021 20:30:09 UTC.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
WUXI APPTEC CO., LTD. 
